HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

• DOI: 10.1016/j.isci.2023.106143
• Publication Date: 2023-02-04T16:57:58Z
• Authors: Xiaoqing Shi; Jiage Ding; Yanyan Zheng; Jiawei Wang; Navid Sobhani; Praveen Neeli; Gang Wang; Junnian Zheng; Dafei Chai
• Keywords: PLGA; HMGB1; CTL*

Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited subcutaneous tumor growth, while increasing infiltration CD8+T cells and DCs. Furthermore, induced strong CTL effect promoted functional cell proliferation. Intriguingly, depletion assay proved that therapeutic dependent on antigen-specific immune responses. In rechallenge experiment, provided long-lasting resistance to growth contralateral by inducing memory Collectively, could induce inhibit progression re-attack. Therefore, combined might be served as an anti-tumor strategy against HCC.